Foghorn Therapeutics (FHTX) Receivables (2021)
Foghorn Therapeutics' (FHTX) quarterly Receivables came in at $300.0 million in Q4 2021.
Foghorn Therapeutics (FHTX) Receivables (2021) Analysis & Trends
Foghorn Therapeutics' Receivables history runs 1 years deep, the most recent figure standing at $300.0 million for Q4 2021.
- On a quarterly basis, Receivables changed N/A year-over-year to $300.0 million in Q4 2021; TTM through Dec 2021 was $300.0 million, a N/A change from a year earlier, with the FY2021 full-year figure at $300.0 million, changed N/A from the prior year.
- Receivables held at $300.0 million in Q4 2021 per FHTX's latest filing.
- Across five years, Receivables topped out at $300.0 million in Q4 2021 and bottomed at $300.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 300.00 Mn |